You are the Director of the National Bioethics Commission who is responsible for assessing the ethical feasibility and oversight of a nationwide gene sequencing program. The project named GeneFuture, aims to sequence the DNA of every newborn child and store it in a centralized national database. The objective is to identify genetic predispositions to serious diseases early in life, allowing for preventive treatment and personalized medicine. Over 100,000 babies have already been enrolled in the pilot phase of the program. The government claims that this move is a landmark step in public health advancement. However, collection of newborn genetic data raises significant ethical concerns, particularly around informed consent, which may not fully capture parents' understanding of the long-term risks involved. Once gathered, this sensitive data could be misused for purposes such as surveillance, insurance discrimination, or commercial marketing by third parties. Uncertainty over data ownership—whether it lies with the state, parents, or the individual as they mature—further complicates the issue. The involvement of private tech and pharmaceutical companies heightens fears of commercial exploitation, especially in the absence of clear mechanisms for individuals to withdraw consent or delete their genetic information upon reaching adulthood. (a) What are the ethical issues you perceive in the implementation of the GeneFuture program? (b) Identify the conflicting interests of different stakeholders in this case. (c) What guiding ethical principles would you recommend for implementation of this project?
Simrandeep Kaur, AIR 15, 2025
The GeneFuture project in this case showcases the complexities of the data collection, storage & consent management. It raises ethical questions on data integrity, accountability and transparency.
a) Ethical Issues perceived
1. lack of stringent data protection law → weak social contract b/w govt and citizens on data 2. long term data breaching for surveillance & profits v/s Short-term gains of limited consent of the parents 3. Non-transparency on ownership of data → State, Parents, Individual. 4. lack of maturity of Infants → Against Kantian dictum of individuals as ends in themselves. 5. Commerce without morality (Gandhian Sin) if companies breached personal data for profits - risking the dignity & informed choices of individuals. 6. Commodification of Humanity:- (Dehumanized data)
b) Conflicting Interests of Diff. Stakeholders
| Interest | v/s | Interest | |---|---|---| | Govt's data gathering to prevent life threatening diseases, Social justice | v/s | Pharma Companies' intent in tailored medicine for profit maximization | | Parents' limited awareness of novel genetic data | v/s | future of the children - privacy, dignity | | Deemed medical consent (DPDP Act 2023) - can't withdraw consent. | v/s | unambigous, clear & informed data consent of formations. |
c) Ethical guidelines for this project
1. Accountability Mapping Parents → can withdraw consent Govt: → zero tolerance to data breaches Pharma companies → informed use of data (not for profit). 2. Transparency in the project → Participative scrutiny of parents & children for lifelong. 3. Clear mechanisms for withdrawl of the consent → Autonomy of the Individual. 4. J.S. Mill's Harms Principle:- gathering data limited to social good & preventing any social harm 5. Third Party Auditing & Monitoring for independent accountability.
In this way, Transparency & Accountability act as disinfectant for any scope of corruption or malpractices.